# Cellectis (stock symbol: CLLS) Logo in transparent PNG format

## Cellectis Logo large

### Cellectis Logo large Download PNG (53.72 KB)

![Cellectis Logo large Download PNG (53.72 KB)](/img/orig/CLLS_BIG-6039a417.png)

## Cellectis Logo icon format

### Cellectis Logo icon format Download PNG (49.36 KB)

![Cellectis Logo icon format Download PNG (49.36 KB)](/img/orig/CLLS-13037a2f.png)

## About Cellectis

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

1. Website domain: cellectis.com
2. Employees: 294
3. Marketcap: $0.10 Billion USD


## Categories
- [x] ðŸ‡«ðŸ‡· France
- [x] ðŸ’Š Pharmaceuticals
- [x] ðŸ§¬ Biotech
